x
Disclaimer
This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
BrainsWay’s flagship technology — Deep Transcranial Magnetic Stimulation (Deep TMS) – is broadening and deepening the capabilities of TMS beyond what is currently thought possible.
BrainsWay is continuously seeking to expand its platform, achieving outcomes that surpass traditional medical solutions. Through ongoing investment in R&D and in research initiatives ranging from large-scale multicenter trials to personalized medical studies, BrainsWay represents the next-generation of treatment options for Major Depression and OCD.
Well-positioned as a leader in this rapidly-expanding field, BrainsWay is changing the future of mental health.
Treat Depression & OCD with BrainsWay’s Deep TMS
For
Patients
- FDA-cleared treatment
- Effective, even when medication doesn’t work*
- Short 20-minute sessions
- Non-invasive
- No systemic side effects
- MDD treatment is covered by Medicare and a majority of private insurers
Our Treatments
*See response and remission rates in the MDD and OCD treatment pages
For Healthcare
Professionals
- Clinically Proven
- Deeper, Broader Stimulation
- Most robust clinical pipeline
- Financially attractive business model
- Best-in-class customer support
- Provide an effective alternative for your treatment-resistant patients
BrainsWay Can Help These Brain Disorders
-
Obsessive Compulsive Disorder (OCD) Treatment
BrainsWay Introduces the First FDA Cleared (De-Novo) Non-invasive Medical Device for the Treatment of OCD. -
Major Depressive Disorder (MDD) Treatment
Major Depressive Disorder is a neuropsychiatric disorder that is expressed in emotional, physiological and behavioral effects.
BrainsWay By The Numbers
500K+
TREATMENTS DELIVERED
17
COUNTRIES
90%
OF POPULATION IS COVERED BY REIMBURSEMENT